NovaBay Pharmaceuticals, Inc.(NBY)Earnings, Financials & Key Ratios
NBY•AMEX
$1.47
Price updated Jun 20, 2026
AboutNovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Show more
- Revenue$10M-6.4%
- EBITDA-$5M-45.7%
- Net Income-$7M+25.1%
- EPS (Diluted)-2.53+98.2%
- Gross Margin66.26%+13.9%
- EBITDA Margin-55.8%-55.7%
- Operating Margin-59.7%-52.2%
- Net Margin-73.85%+19.9%
- ROE-453.56%-226.2%
NBY Price & Volume
NovaBay Pharmaceuticals, Inc. (NBY) stock price & volume — 10-year historical chart
Loading chart...
NovaBay Pharmaceuticals Faces Severe Structural Revenue Contraction
Investment Thesis • Updated 2025Q3
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Existential liquidity crisis
Key Thesis Takeaways
- NovaBay Pharmaceuticals exhibits a deteriorating financial profile characterized by a 78.7% year-over-year revenue decline as of 2025Q3 and persistent operational losses.
- The company's reliance on external financing to cover ongoing deficits, coupled with an accumulated deficit of $183.8 million, suggests significant long-term solvency risks.
- Investors should remain cautious as the firm struggles to stabilize its core Avenova product line amidst a precarious liquidity position.
Verdict Logic
Negative: The company's fundamental instability is highlighted by a 78.7% revenue decline and a precarious cash position that necessitates further dilutive financing to maintain operations.
NBY Growth Metrics
NovaBay Pharmaceuticals, Inc. (NBY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.96%
5 Years8.19%
3 Years-1.4%
TTM-74.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM132.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM101.12%
Return on Capital
10 Years-198.76%
5 Years-96.22%
3 Years-118.55%
Last Year-218.85%
Peers Comparison
Key metrics vs top competitors for NovaBay Pharmaceuticals, Inc. (NBY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.47 | $8.84M | -0.58 | -6.45% | -73.85% | -453.56% | — | |
| $2.19 | $17.74M | -1.01 | 1.84% | -60.17% | -148.91% | — | |
| $0.07 | $342.01K | -0.04 | -35.82% | -709.4% | -453.74% | — | |
| $0.58 | $2.62M | -0.13 | — | — | -177.32% | — | |
| $0.61 | $6.79M | -0.18 | — | -823.34% | -60.07% | — | |
| $10.55 | $254.3M | 19.54 | -9.25% | 45.8% | 9.75% | — |
Compare NBY vs Peers
NovaBay Pharmaceuticals, Inc. (NBY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NBY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NBY Frequently Asked Questions
NovaBay Pharmaceuticals, Inc. (NBY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is NovaBay Pharmaceuticals, Inc.'s revenue?
NovaBay Pharmaceuticals, Inc. (NBY) reported $2.8M in revenue for fiscal year 2024.
How fast is NovaBay Pharmaceuticals, Inc. growing?
NovaBay Pharmaceuticals, Inc. (NBY) saw revenue decline by 6.4% over the past year.
Is NBY profitable?
Yes, NovaBay Pharmaceuticals, Inc. (NBY) is profitable, generating $3.2M in net income for fiscal year 2024 (-73.8% net margin).
Dividend & Returns
What is NBY's return on equity?
NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -453.6%. Negative ROE indicates the company is unprofitable.
What is NovaBay Pharmaceuticals, Inc.'s free cash flow?
NovaBay Pharmaceuticals, Inc. (NBY) had negative free cash flow of $7.0M in fiscal year 2024, likely due to heavy capital investments.